Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
804天前
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
1059天前
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
1086天前
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
1158天前
Bay Street Likely To Open On Mixed Note
Canadian shares are likely to open on a mixed note on Thursday, tracking earnings updates, and commodity prices. The end to the U.S. government shutdown following President Donald Trump signing a short term bill is likely to aid sentiment.
RTTNews
|
1小時18分鐘前
European Stocks Pare Early Gains As Markets Digest Earnings, Economic News
European stocks gave up early gains and are broadly lower Thursday afternoon as investors look ahead to some crucial economic data following the longest federal government shutdown in U.S. history coming to an end after President Donald Trump signed a funding package.
RTTNews
|
1小時44分鐘前
Disney Q4 Profit Beats Street, Revenues Miss; Sees Adj. EPS Growth, Plans $7 Bln Buyback; Stock Down
Shares of Walt Disney Co. were losing around 4 percent in the pre-market activity on Thursday after the media and entertainment major reported nearly flat revenues in its fourth quarter below market estimates, even though profit beat the Street. Further, the firm said it expects double digit year-over-year growth in adjusted earnings per share for fiscal 2026 and 2027, and targets doubling share
RTTNews
|
1小時57分鐘前
FTSE 100 Moderately Lower At Noon As Investors React To Earnings, GDP Data
U.K.'s benchmark FTSE 100 is down in negative territory around noon on Thursday with investors digesting a slew of earnings updates, and data showing a marginal increase in the nation's economic growth in the third quarter.
RTTNews
|
2小時38分鐘前
